Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Olivia Hayes, whose husband was allegedly killed by an illegal immigrant, told Fox News she believes President Donald Trump's ...

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Hims & Hers Health (NYSE:HIMS) recently announced a partnership with Novo Nordisk to enhance obesity care access in the U.S., coinciding with a notable 24% increase in its stock price over the last ...

We recently published a list of 10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks. In this article, we are ...

SHOPPING: PSD underwear takes your style to the next level. Bold designs and unmatched comfort for a statement that starts ...

OKLAHOMA CITY (AP) — A family in Oklahoma was wrongly targeted when federal immigration agents raided their home while ...

AT LAST! may have been a long time coming, but the Oak Cliff-based nonprofit is going places. The nation's first "boarding ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit ...

A sweeping proposal under review by the City of Richmond Planning Commission could drastically reshape where smoke and vape ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.